Metagenomi (MGX)

• Market cap: $62M
• 1 day: -5.17%
• 5 days: -6.78%
• 1 month: -11.29%
• 3 months: -11.29%
• 6 months: 13.79%
• Year to date: -56.46%
• 1 year: -57.25%
• 5 years: -84%
• 10 years: -84%
• Sector: Healthcare
• Industry: Biotechnology

About: Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

Employees: 124